December 3, 2018
December 3, 2018 —
Following the FDA’s approval of chimeric antigen receptor (CAR) T-cell therapies for the treatment of certain types of non-Hodgkin lymphomas, UC San Diego Health was the first medical center in San Diego to be certified to offer this type of immunotherapy outside of a clinical trial.
November 30, 2018
November 30, 2018 —
A randomized clinical trial involving 97 medical centers in 20 countries, including Moores Cancer Center at UC San Diego Health, found that treating patients with head and neck cancer with the immunotherapy drug pembrolizumab is more effective and less toxic than standard chemotherapy.
November 29, 2018
November 29, 2018 —
Moores Cancer Center at UC San Diego Health launched the Pancreatic Cancer Prevention and Screening Clinic in an attempt to reduce the number of people who develop the disease and improve survival for those who do. Every day in the U.S., 145 people are diagnosed and every 12 minutes someone dies.
November 20, 2018
November 20, 2018 —
A team of University of California San Diego School of Medicine researchers have been awarded a $1 million Stand Up To Cancer (SU2C) grant to test drugs that block signals that play a critical role in driving growth and progression of pancreatic cancer.
October 24, 2018
October 24, 2018 —
The mechanism leading to development of type 1 diabetes remains a mystery, hampering the ability to find new ways to prevent, treat or even cure this condition. With a new $3.3 million grant, University of California School of Medicine researchers hope to create a high resolution reference map of pancreatic cells that will identify molecular changes that arise during type 1 diabetes.
October 12, 2018
October 12, 2018 —
Tamara Strauss has been living with high-grade, stage IV pancreatic neuroendocrine cancer for more than three years. Current treatments, although effective for her, are highly toxic. Tamara enrolled in a first-of-its-kind, pilot study at Moores Cancer Center at UC San Diego Health to test a personalized vaccine using her unique cancer mutations to boost an anti-tumor immune response.
October 10, 2018
October 10, 2018 —
Early adoption of tobacco control efforts in California led to fewer people ever smoking, reduced the amount used by those who do smoke and helped smokers quit at a younger age — when their risk of developing lung cancer is lowest. As a result, lung cancer deaths are 28 percent lower in California compared to the rest of the country and the gap is widening each year by almost a percentage point.
August 8, 2018
August 8, 2018 —
To understand why some patients with appendix cancer respond to standard treatment while others do not, University of California San Diego School of Medicine and Moores Cancer Center researchers, in collaboration with Foundation Medicine, performed genetic profiling on 703 appendiceal tumors — the largest such study of this disease to date — to compare mutations present in both cancer types.
July 25, 2018
July 25, 2018 —
In a study published online July 25 in the journal Nature, University of California San Diego School of Medicine researchers identified a signaling pathway that activates the NLRP3 inflammasome implicated in several severe chronic inflammatory disorders.
July 9, 2018
July 9, 2018 —
Through x-ray crystallography and kinase-inhibitor specificity profiling, University of California San Diego School of Medicine researchers, in collaboration with researchers at Peking University and Zhejiang University, reveal that curcumin, a natural occurring chemical compound found in the spice turmeric, binds to the kinase enzyme dual-specificity tyrosine-regulated kinase 2 (DYRK2) at the atomic level. This previously unreported biochemical interaction of curcumin leads to inhibition of DYRK2 that impairs cell proliferation and reduces cancer burden.
